Analysts Anticipate CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Will Announce Earnings of -$0.30 Per Share

Equities analysts expect CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) to report earnings per share (EPS) of ($0.30) for the current quarter, according to Zacks. Zero analysts have provided estimates for CymaBay Therapeutics’ earnings, with estimates ranging from ($0.33) to ($0.24). CymaBay Therapeutics posted earnings of ($0.34) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.8%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.37) to ($0.95). For the next fiscal year, analysts expect that the business will report earnings of ($1.27) per share, with EPS estimates ranging from ($1.46) to ($0.82). Zacks’ EPS calculations are an average based on a survey of research firms that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). During the same period in the prior year, the business posted ($0.25) earnings per share.

CBAY has been the topic of a number of research reports. Oppenheimer lowered their price target on CymaBay Therapeutics to $12.00 and set a “na” rating on the stock in a report on Monday, May 16th. StockNews.com cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. HC Wainwright lowered their price target on CymaBay Therapeutics from $12.00 to $10.00 and set a “na” rating on the stock in a report on Monday, May 16th. B. Riley lowered their price target on CymaBay Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CymaBay Therapeutics in a report on Friday, April 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, CymaBay Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.39.

NASDAQ CBAY opened at $2.03 on Friday. The stock has a market capitalization of $171.90 million, a price-to-earnings ratio of -1.53 and a beta of 1.08. The company has a current ratio of 13.68, a quick ratio of 13.68 and a debt-to-equity ratio of 0.73. The business’s 50 day moving average is $2.59 and its two-hundred day moving average is $3.08. CymaBay Therapeutics has a 12-month low of $1.67 and a 12-month high of $5.06.

Several institutional investors have recently modified their holdings of CBAY. Morgan Stanley raised its position in shares of CymaBay Therapeutics by 53.5% in the 1st quarter. Morgan Stanley now owns 116,176 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 40,484 shares during the period. Barclays PLC raised its position in shares of CymaBay Therapeutics by 215.4% in the 3rd quarter. Barclays PLC now owns 28,332 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 19,348 shares during the period. Citigroup Inc. raised its position in shares of CymaBay Therapeutics by 54.2% in the 3rd quarter. Citigroup Inc. now owns 12,024 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 4,225 shares during the period. Rockefeller Capital Management L.P. raised its position in shares of CymaBay Therapeutics by 25.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 124,000 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 25,000 shares during the period. Finally, GSA Capital Partners LLP raised its position in shares of CymaBay Therapeutics by 102.2% in the 3rd quarter. GSA Capital Partners LLP now owns 264,224 shares of the biopharmaceutical company’s stock worth $964,000 after buying an additional 133,552 shares during the period. 78.34% of the stock is currently owned by institutional investors.

About CymaBay Therapeutics (Get Rating)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.

Recommended Stories